Jurgi Camblong Sells 2,600 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 2,600 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $4.85, for a total value of $12,610.00. Following the transaction, the chief executive officer owned 3,731,450 shares in the company, valued at approximately $18,097,532.50. This trade represents a 0.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total value of $12,150.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.77, for a total value of $21,398.22.

SOPHiA GENETICS Price Performance

Shares of SOPH opened at $4.73 on Friday. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS SA has a 1 year low of $2.58 and a 1 year high of $5.70. The stock has a market cap of $323.96 million, a P/E ratio of -9.27 and a beta of 1.04. The stock’s 50-day moving average price is $4.76 and its two-hundred day moving average price is $4.68.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. On average, equities analysts predict that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Wall Street Analyst Weigh In

SOPH has been the topic of a number of recent analyst reports. Guggenheim raised their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $7.00 price target on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SOPHiA GENETICS presently has an average rating of “Hold” and an average target price of $7.00.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional buying: UBS Asset Management and Akre Capital materially increased positions recently (UBS added ~5.4M shares). That sizable institutional demand can support the stock and offsets some insider selling. MarketBeat Institutional/Insider Summary
• Neutral Sentiment: Multiple senior executives (CEO Jurgi Camblong, CFO George Cardoza, CTO Abhimanyu Verma, President Ross Muken and others) executed several small sales (roughly 600–2,700 shares each) under Rule 10b5‑1 plans to cover tax withholding tied to vesting awards; these are disclosed in SEC Form 4 filings. Representative SEC filing (CEO): CEO Form 4
• Neutral Sentiment: Analyst views are mixed but skew positive: Guggenheim and BTIG have reiterated/raised targets to ~$7 with buy ratings, while one service retains a sell. Those analyst targets imply upside vs. current levels and help explain why institutional buyers remain active. Analyst Coverage
• Negative Sentiment: Collective insider selling can create short‑term downward pressure — even though each trade is small and pre‑arranged, the clustered timing (multiple execs selling within the same days) contributed to intraday selling and likely drove the price lower. Summary of the insider trade reports: InsiderTrades article

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds have recently modified their holdings of the business. Green Alpha Advisors LLC raised its position in shares of SOPHiA GENETICS by 10.8% during the fourth quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock worth $213,000 after purchasing an additional 4,444 shares during the period. Dimensional Fund Advisors LP raised its position in shares of SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares during the period. Savvy Advisors Inc. acquired a new stake in shares of SOPHiA GENETICS during the third quarter worth about $48,000. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS during the third quarter worth about $49,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS during the fourth quarter worth about $49,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.